Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Rhabdomyosarcoma 2Medulloblastoma 2Uveal Melanoma 1Sarcoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Laryngeal Diseases 1Glioma 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 2Radiosurgery 2Cyclophosphamide 2pentetreotide 1fludarabine phosphate 1entinostat 1Thrombopoietin 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1LY2940680 1Ipilimumab 1Interleukin-13 1Immunologic Techniques 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Etoposide 1Cryosurgery 1Carboplatin 1CTLA-4 Antigen 1Biopsy 1Amplified Fragment Length Polymorphism Analysis 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × LY2940680 × CNS × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡